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Abstract
Although a small percentage of patients with critical aortic stenosis do not develop left ventricle
hypertrophy, increased ventricular mass is widely observed in conditions of increased afterload.
There is growing epidemiological evidence that hypertrophy is associated with excess cardiac
mortality and morbidity not only in patients with arterial hypertension, but also in those undergoing
aortic valve replacement. Valve replacement surgery relieves the aortic obstruction and prolongs
the life of many patients, but favorable or adverse left ventricular remodeling is affected by a large
number of factors whose specific roles are still a subject of debate. Age, gender, hemodynamic
factors, prosthetic valve types, myocyte alterations, interstitial structures, blood pressure control
and ethnicity can all influence the process of left ventricle mass regression, and myocardial
metabolism and coronary artery circulation are also involved in the changes occurring after aortic
valve replacement. The aim of this overview is to analyze these factors in the light of our
experience, elucidate the important question of prosthesis-patient mismatch by considering the
method of effective orifice area, and discuss surgical timings and techniques that can improve the
management of patients with aortic valve stenosis and maximize the probability of mass regression.
Review
Left ventricular pressure overload due to aortic valve sten-
osis (AS) leads to a marked hypertrophic response of the
myocardium, which is probably an adaptative reaction
aimed at normalizing the increased wall stress. Although
a small percentage of patients with critical AS do not
develop left ventricle (LV) hypertrophy, increased LV
thickness is widely observed in conditions of increased
afterload and is usually accompanied by a parallel deposi-
tion of new sarcomers. This compensatory response seems
to maintain cardiac performance despite the high intrac-
avitary systolic pressure [1,2].
AS is a common disorder and the most frequent acquired
valvular disease in developed countries. The natural his-
tory of symptomatic patients is dismal, and even asymp-
tomatic subjects with a significant stenosis face a risk of
sudden death that has been reported to be ~1% per year
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ditions such as arterial hypertension, AS, aortic coartac-
tion and hypertrophic obstructive cardiomyopathy, and
there is increasing epidemiological evidence that it is asso-
ciated with excess cardiac mortality and morbidity [5-9].
Moreover, in isolated AS, it has recently been shown that
increased LV mass alone predicts systolic dysfunction and
heart failure regardless of the severity of the valvular
obstruction. For this reason, LV hypertrophy can be inter-
preted as being a synonymous with a maladaptive
response to aortic valve disease rather than a compensa-
tory reaction [10]. Aortic valve replacement (AVR) surgery
dramatically changes the clinical course of patients with
AS by relieving the high pressure gradient and allowing
the reversal of the LV hypertrophic process. Age-corrected
survival has been reported to be nearly normal after AVR
[11], but there are still some questions as to whether the
ventricular chamber can return to its normal size, and
how rapidly myocardial hypertrophy and LV dysfunction
regress.
What follows is an experience-based review of the factors
involved, and the extent to which the myocardium itself
may recover (favorable remodeling) or deteriorate (adverse
remodeling).
Age
The prevalence of calcific AS increases with age (2–4% of
adults aged more than 65 years) and, as the majority of
patients suffering increased mortality and morbidity due
to aortic valve disorders are elderly [12], it is extremely
important to know whether they may benefit from AVR
and if favorable LV remodeling is probable [13].
Hanayama et al. have recently reported that age is not a
determinant of incomplete mass regression after a mean
follow-up of 3.75 years [14], and Gaudino et al. have pub-
lished a similar finding [15]. Using more accurate 3-D
echocardiography, Kühl et al. consistently observed that
normalization of the LV mass index after one year was not
related to age at the time of surgery [16], but the results of
studies by Lund et al., who developed a preoperative prog-
nostic index specifically conceived for patients with AS
undergoing AVR that included age, indirectly suggest that
age is associated with the LV mass index after 10 years: the
higher scores correlated with a higher LV mass index dur-
ing the postoperative course [17]. Univariate and multi-
variate analysis of our own patient series have not
indicated age as a factor influencing the process of mass
regression even in the subgroup of patients with a pros-
thesis-patient mismatch (PPM) [18,19].
Gender
It is known that there is a gender-related difference in the
development of pressure overload-induced LV hypertro-
phy: after adjusting for body surface area, females have
less mass, more concentric hypertrophy, less wall tension,
fewer alterations in passive elastic properties, higher ejec-
tion fractions and smaller LV volumes [20-22]. The effect
of these gender-related differences in hypertrophy pat-
terns on the recovery and regression of the LV mass index
is still being debated. In their medium-term study,
Hanayma et al. found that the LV hypertrophy index of
females was less likely to regress incompletely [14], and
we have found that female gender is an independent pre-
dictor of greater LV mass regression except in the particu-
lar subgroup of patients with PPM, in whom it plays no
predictive role [18,19]. In the prognostic index developed
by Lund et al., female gender is a neutral factor whereas
male gender adds one point: i.e. it increases the risk of
post-AVR mortality and morbidity [17]. On the contrary,
Del Rizzo et al. found that male gender was an independ-
ent predictor of LV mass regression after AVR with stent-
less bioprostheses [23] although, some years later,
Gelsomino et al, using another type of stentless xenograft,
found that it negatively affected LV mass regression [24].
However, gender differences in LV adaptation do not
seem to influence survival after AVR [15,21,25,26].
Finally, the results of the 3-D echocardiography study by
Kuhl et al. indicate that 1-year LV mass index normaliza-
tion is unrelated to gender [16].
Hemodynamic factors
The hemodynamic advantage of AVR arises from its ability
to minimize postoperative gradients and favor the nor-
malization of LV mass and function but, although it intu-
itively seems to be quite important, the influence of
hemodynamic variables on the extent of LV mass regres-
sion is controversial.
A PPM is considered such when the effective orifice area
(EOA) of the implanted prosthesis is less than that of the
normal human valve: i.e. too small in relation to body
surface area (BSA). This is a crucial parameter when eval-
uating the performance of valve substitutes: some authors
have found that PPM leads to higher mortality rates
[27,28] and others have found no effect on overall sur-
vival [14,15,29], but there is considerable evidence that it
has detrimental implications in terms of LV workload
[19,23,29,30]. Moreover, its clinical impact seems to be
related to both its severity and LV function, thus underlin-
ing the fact that a diseased ventricle is much more sensi-
tive to increased afterload [27]. Indexed EOA (EOA
divided by BSA) is decidedly a more physiological param-
eter to adopt in defining PPM, whereas the labeled or
internal geometric size of the prosthesis may be mislead-
ing [31,32]. It has been demonstrated that, in order to
avoid any significant gradient at rest or during exercise,
the indexed EOA of a prosthetic aortic valve should ideally
be no less than ~0.8–0.9 cm2/m2. However, in clinical
practice, post-AVR indexed EOA be less than this for aPage 2 of 9
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reduced because of calcifications, fibrosis, hypertrophy in
the LV outflow tract, or because the structural support of
the valve prosthesis may be quite bulky (especially in
older models) and create a relative obstruction to flow.
Moreover, the procedures for implanting an adequate
prosthesis in a small and severely calcified aortic root
(annulus enlargement, root replacement, LV outflow
enlargement) can be technically more difficult and often
require a longer period of aortic cross-clamping. They may
also be contraindicated in some situations: for example,
the presence of heavy and extended calcifications around
the coronary ostia does not allow root replacement and
coronary artery reimplantation. Consequently, the per-
ceived balance between the increased preoperative risk of
the more complex operation needed to avoid a potentially
suboptimal late clinical outcome due to a small prosthe-
sis, and the chances of the patient experiencing meaning-
ful long-term survival and quality of life determines the
surgeon's choice of prosthesis type and size.
The true incidence of PPM can only be discovered using
the EOA method to evaluate the prosthesis performance.
This has repeatedly shown that the presence of PPM seri-
ously hampers LV mass regression [18,23], whereas older
comparisons based on labeled prosthesis size found pros-
theses of different sizes led to similar degrees of LV mass
reduction even in the case of PPM [33,34]. One expression
of the potential severity of a mismatch is given by the rela-
tionship showing that the transvalvular gradient increases
exponentially with a decrease in indexed EOA. We have
found an independent relationship between indexed EOA
and the extent of LV mass regression after AVR. Further-
more, the pattern of LV remodeling was influenced by
PPM, with a smaller decrease in chamber internal dimen-
sion in patients with than in those without a mismatch
[18]. We also found that the degree of mass regression
may vary markedly from one patient to another. Some
patients with PPM may therefore show a substantial
regression in LV hypertrophy despite the presence of a rel-
atively high residual transvalvular gradient because the
regression in LV mass in such patients is independently
influenced by the relative increase in valve EOA achieved
by AVR (Fig. 1) [19]. This explains why some authors have
reported that patients with PPM and/or small prostheses
show significant reductions in LV mass.
In conclusion, even in the presence of PPM, surgery usu-
ally improves hemodynamics. The extent of the improve-
ment can be quite important and it is likely that the best
results can be expected if PPM is completely avoided.
Moreover, the relationship between gradients and
indexed EAO is curvilinear, and the implications for a
given patient are directly related to his/her original and
final positions on the indexed EAO-gradient curve
[30,31]. One practical approach to reduce the impact of
PPM is to begin by determining preoperatively the mini-
mum EOA that the implanted prosthesis should have to
avoid moderate-to-severe PPM. This is done by multiply-
ing the patient's BSA (calculated on the basis of his/her
weight and height) by 0.85 cm2/m2: for example, if the
BSA is 1.7 cm2/m2, the minimum EOA is 1.7*0.85 = 1.44
cm2. The next step is verifying which of the available pros-
theses have the same or a larger EOA by looking at the
widely available published data reported in the literature
or provided by the manufacturers (Tab.1) [27,30]. In this
way, at the time of the operation, the surgeon can attempt
to implant one of the selected prostheses or, if technically
possible, perform an aortic root enlargement or other pro-
cedure to enable the accommodation of a valve with the
adequate EOA.
Valve type
Pibarot et al. have reported the relative positions of differ-
ent types of biological aortic valve substitutes on the expo-
nential curve linking the transvalvular gradient and
indexed EOA [30]. The majority of patients with a stented
prosthesis have an indexed EAO of ≤ 0.85 cm2/m2 and are
therefore on the steep portion of the curve, where the gra-
dients are relatively high, whereas most patients with a
stentless prosthesis and almost all of those undergoing an
aortic homograft or pulmonary autograft have a larger
Influence of the relative increase of EOA after AVR on LV massFigure 1
Influence of the relative increase of EOA after AVR 
on LV mass. Correlation between absolute left ventricular 
mass (LVM) index regression and increased indexed effective 
orefice area (r = -0.31; r2 = 10%, p = 0.001). (Reprinted from 
Annals of Thoracic Surgery, Vol. 79, Tasca G et al, Impact of the 
improvement of valve area achieved with aortic valve replacement 
on the regression of left ventricular hypertrophy in patients with 
pure aortic stenosis, Page 1294, © 2005, with permission from 
The Society of Thoracic Surgery) [19].Page 3 of 9
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where the gradients are relatively low [30,35]. It is possi-
ble that the consequences on LV mass regression may
eventually be predicted on the basis of these findings, but
it is currently hazardous to do so for a number of reasons.
Firstly, there is a lack of randomized prospective studies of
homogeneous cohorts relating valve types and their bene-
fits in terms of mass reduction. Secondly, there are differ-
ences in the indications, availability and technical risks
related to the various valve substitutes: i.e. the hypotheti-
cal superiority of mechanical prostheses in terms of hyper-
trophy regression does not change the indication for a
biological prosthesis in the elderly. Thirdly, recently pub-
lished studies have failed to demonstrate any robust
advantage of a particular type of substitute. Like Gaudino
et al. very recently [15], Hanayma et al. found that the type
of prosthesis did not predict the extent of postoperative
LV mass regression in a long-term prospective study com-
paring stented porcine valves, stented pericardial prosthe-
ses, stentless porcine valves, and tilting and bileaflet
mechanical prostheses [14]; furthermore, Kühl et al.
found that 1-year normalization of the LV mass index
studied by means of 3-D echocardiography was not
related to valve type [16], and a tentative meta-analysis of
501 patients by Sharma et al. revealed no substantial
advantage of stentless over stented valves in terms of the
rate of LV mass regression [26]. Also in prospective, mul-
ticenter randomized comparisons there were similar
reductions in LV mass at 12 months with both stented and
stentless valves despite significant differences in indexed
EOA and peak flow velocity in favor of the stentless valves
[Circ 2005]. We have studied stented and stentless biolog-
ical valves and mechanical prostheses in the challenging
subgroup of patients with PPM and concluded that valve
type was not one of the factors influencing mass regres-
sion [19]. In fact, we feel that other factors must also be
considered (see Non-hemodynamic factors and Conclu-
sions) and that any comparisons must always be made at
homogeneous values of indexed EOA because stratifica-
tion by prosthesis diameter or size is probably erroneous.
Myocardial metabolism
It has been shown that LV hypertrophy can be accompa-
nied by alterations in myocardial high-energy phosphate
metabolism [36], but it is only recently that the availabil-
ity of magnetic resonance (MR) spectroscopy has made it
possible to study these alterations after AVR [37]. Changes
in myocardial high-energy phosphate metabolism are
usually expressed as changes in the phosphocreatine-to-
adenosine triphosphate (PCr-ATP) ratio, which is reduced
in AS pressure overload. Beyerbacht et al. attributed pre-
AVR findings of a reduced ratio at rest to myocardial stress
and ischemia: i.e. a hypertrophy-induced imbalance
between myocardial oxygen supply and demand. Conse-
quently, a recovery in the post-AVR myocardial PCr-ATP
ratio accompanied by a reduction in the LV mass index (as
revealed by studying LV geometry and function) may indi-
cate that the reduced pressure overload has decreased the
metabolic demand of the myocardium and improved cor-
onary blood flow. The same authors also reported a statis-
tically significant correlation between myocardial high-
energy phosphate metabolism and LV diastolic function
[37].
Diastole
Doppler echocardiographic alterations in LV diastolic
function occur early under conditions of pressure over-
load and precede the increase in LV mass. It is not clear
whether the early reduction in afterload immediately after
AVR (when hypertrophy is still present) also leads to
improved diastolic function. Assessments of the time con-
stant of relaxation, peak filling rate and the constant of
myocardial stiffness by Villari et al. after 89 ± 21 months
have shown that diastolic function normalizes only late
after AVR [38]. This indicates that the process of favorable
remodeling (i.e. the regression of myocardial hypertrophy
and interstitial fibrosis) is slow and may allow diastolic
normalization only after its completion. Hess et al. previ-
ously made another important contribution based on
endomyocardial biopsies obtained before and after sur-
gery, and simultaneous echocardiography and pressure
measurements, which showed that diastolic alterations
Influence of LV histological findings on outcome after AVRFigure 2
Influence of LV histological findings on outcome after 
AVR. Cumulative survival after the operation in relation to 
muscle cell nucleus volume. Five- and 7-year survivals were 
83 ± 7% and 83 ± 7%, respectively, for a nucleus volume of ≤ 
820 μm3 ( ____ ), and 74 ± 10% and 49 ± 14%; respectively, 
for a nucleus volume of >820 μm3 ( ------ ). (Lund O, et al. 
Myocardial structure as a determinant of pre- and postoperative 
ventricular function and long-term prognosis after valve replace-
ment for aortic stenosis. Eur Heart J 1998,19:1099–1108, by 
permission of Oxford University Press) [42].Page 4 of 9
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[39]. Their findings of a decrease in muscle fiber diameter
and a relative increase in interstitial fibrosis, without any
change in fibrous content, showed that the post-AVR
regression of myocardial hypertrophy was accompanied
by an increase in myocardial stiffness due to the relatively
slower remodeling of the extracellular compartment.
These conditions are not incompatible with the full nor-
malization of the diastolic parameters described by Villari
et al. because the follow-up of their study was longer.
Another contribution comes from Ikonomidis et al., who
assessed the effect of residual pressure overload on the
regression of LV hypertrophy and its relationship to
diastolic function two months and four years after AVR
[40]. Isovolumic relaxation significantly decreased from
93 ± 20 ms to 78 ± 12 ms to 81 ± 15 ms, and deceleration
time from 241 ± 102 ms to 205 ± 77 ms to 226 ± 96 ms.
The prolonged isovolumic relaxation time was associated
with significant septal and posterior wall hypertrophy,
whereas the prolonged deceleration time was related to a
high residual gradient. They concluded that LV diastolic
function improves early after surgery in parallel with the
reduction in the aortic gradient, but prolonged Doppler
indices of myocardial relaxation and ventricular filling
were observed in patients with significant LV hypertrophy
and a residual pressure gradient soon after surgery. They
also reported that diastolic function remained improved
four years postoperatively [40].
In a recent longer follow-up study of a large and represent-
ative population of patients with a mean age of 67 ± 8.6
years, Gjertsson et al. [41] evaluated diastolic function by
integrating mitral and pulmonary venous flow data. The
patients were divided into two groups on the basis of
whether their filling pattern indicated normal/mild or
moderate/severe diastolic dysfunction. Eighty-three per-
cent of the patients showed signs of LV hypertrophy pre-
operatively; this had decreased to 29% (p < 0.001) after
two years but no further decrease was found after 10 years.
Deceleration time decreased during the follow-up,
whereas the E/A and S/D ratios increased. The percentage
of patients with moderate/severe diastolic dysfunction
remained unchanged between the preoperative and 2-year
examinations (7% vs 13%; p = 0.27), but increased after
10 years (61%; p < 0.0001). Although the findings regard-
ing the degree of LV mass reduction agree with those of
other investigators [38,40], the prevalence of disturbed
diastolic function was unexpected and related by the
authors to the older age of their study cohort. This may
also imply a more advanced degree of interstitial fibrosis
due to longer exposure to pressure overload, and a conse-
quently limited possibility of favorable remodeling: i.e.
severe diastolic dysfunction indicates non-reversible myo-
cardial changes. Although distinguishing the effects of age
and long-term exposure to increased afterload is impor-
tant in terms of AVR timing, it has still not been done.
Gjertsson et al. did not make a specific analysis in relation
to PPM (see Hemodynamic factors), but the patients with
the worst diastolic function after 10 years had a signifi-
cantly higher prosthesis gradient [41]. This indirectly fur-
ther underlines the importance of avoiding PPM in order
to optimize outcomes.
Table 1: Normal reference values of EOA for the prosthetic aortic valves. EOA is expressed as mean values available in the literature
No. of Patients,* % Prosthetic Valve Size, mm
19 21 23 25 27 29
Stented bioprosthetic valves
Medtronic Intact 129 (10.2) 0.85 1.02 1.27 1.40 1.66 2.04
Medtronic Mosaic 390 (30.8) 1.20 1.22 1.38 1.65 1.80 2.00
Hancock II 53 (4.2) ... 1.18 1.33 1.46 1.55 1.60
Carpentier-Edwards Perimount 59 (4.7) 1.10 1.30 1.50 1.80 1.80 ...
St. Jude Medical X-cell 21 (1.7) ... ... ... ... ... ...
Stentless bioprosthetic valves
Medtronic freestyle 368 (29.1) 1.15 1.35 1.48 2.00 2.32 ...
St Jude Medical Toronto SPV 60 (4.7) ... 1.30 1.50 1.70 2.00 2.50
Mechanical valves
St Jude Medical Standard 151 (11.9) 1.04 1.38 1.52 2.08 2.65 3.23
St Jude Medical Regent 13 (1.0) 1.50 2.00 2.40 2.50 3.60 4.80
MCRI On-X 18 (1.4) 1.50 1.70 2.00 2.40 3.20 3.20
Carbomedics 3 (0.2) 1.00 1.54 1.63 1.98 2.41 2.63
Björk Shiley CC 1 (0.1) ... ... ... ... ... ...
* No. of patients with the prosthesis in the cited study [27]. (Modified from Blais C, et al. Impact of valve prosthesis-patient mismatch on short-term 
mortality after aortic valve replacement. Circulation 2003:108:983–988, by permission of LWW) [27].Page 5 of 9
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The effect of LV systolic function on mass regression has
rarely been investigated in detail. Lund et al. performed
transmural biopsies during AVR and found that the pre-
operative LV ejection fraction (EF) inversely correlated
with myocyte nucleus volume and the fibrous tissue, mus-
cle cell and LV mass indices. The LV mass index 18 months
after AVR was significantly related to the above mentioned
morphological parameters, thus suggesting that favorable
remodeling after the removal of the hypertrophy trigger
may be predetermined by profound changes in hypertro-
phied myocytes and ventricular fibrosis in many patients
[42]. Kühl et al. consistently found that LV mass index
studied by means of 3-D echocardiography was less likely
to normalize one year after AVR in patients with a reduced
preoperative EF [16]. Our own early follow-up findings do
not indicate EF as a factor influencing LV mass regression,
and Hanayama et al. also failed to find any difference in
preoperative EF between the patients with a normal or
abnormal LV mass index after a longer follow-up [14,19].
However, particular attention is required in the subgroup
of patients with severe ventricular dysfunction and certain
surgical strategies may promote LV recovery [35].
Coronary circulation
Epicardial coronary arteries are larger in patients with aor-
tic valve disease, but it has been reported that the appro-
priateness of their cross-sectional areas normalized on the
basis of muscle mass is inadequate, and this contributes to
explain the anginal symptoms that occur in AS: after AVR,
reduced LV hypertrophy and smaller coronary arteries
allow a more adequate match of coronary size and muscle
mass [43]. However, in addition to alterations in epicar-
dial arteries, abnormalities in microcirculatory function
may play a major role in causing the reduced coronary
vasodilator reserve and subendocardial ischemia typically
observed in AS. Reduced diastolic perfusion, and
increased systolic impedance to coronary flow due to
perivascular compression, are considered to be primary
contributors to impaired coronary microcirculatory func-
tion, mainly because of the reduction in maximal myocar-
dial blood flow. The role of favorable post-AVR LV
remodeling in the coronary microcirculation has recently
been investigated by means of positron emission tomog-
raphy and MR. The conclusion was that changes in micro-
circulatory function did not directly depend on LV mass
regression, and it was suggested that reduced extravascular
compression and an increased diastolic perfusion time
may be the main mechanisms improving hyperemic myo-
cardial blood flow and restoring coronary vasodilatation
reserve after AVR [44]. Cheaper, reliable and more accessi-
ble non-invasive tools than positron emission tomogra-
phy are now gaining acceptance as a means of exploring
coronary microcirculation impairment, and it should not
be long before further documentation of post-surgical vas-
cular remodeling is available [45]. AS shares many risk
factors with atherosclerotic coronary artery disease
(CAD), and it is known that concomitant coronary artery
bypass grafting increases the operative risk of AVR. Bieder-
man et al. have recently reported that CAD also has a neg-
ative impact on reverse remodeling, as revealed by means
of the very promising method of intramyocardial MR
imaging [46]. They inferred that the presence of CAD is
sufficient to delay LV mass regression via a number of
putative pathways, notably an inability to reset mRNA sig-
naling and a failure to inactivate the metalloproteinases
that promote interstitial fibrosis and blunt its reabsorp-
tion after AVR, and pointed out the need to reconsider the
timing of surgery in patients with concomitant CAD [46].
Non-hemodynamic factors
Many factors are recognized as influencing the sequence
of biological events that lead to the development of LV
hypertrophy. Hemodynamic load is the fundamental
stimulus, but genotype, gender and other not fully deter-
mined genetic and environmental factors regulate the
growth of LV mass by means of proto-oncogenes, growth
factors, neurohormones and cytokines [47]. The degree of
the resulting structural changes, which may be compensa-
tory or inappropriate but are probably always pathologi-
cal [10], may influence the post-AVR remodeling process.
It is in fact known that the regression potential of a hyper-
trophied LV is only partially influenced by improved
hemodynamics, and some authors have therefore investi-
gated the role of preoperative ultrastructural myocardial
abnormalities. Lund et al. have conducted many studies in
this field and, in 1998, published an interesting paper in
which the findings from transmural biopsies taken during
AVR were related to instrumental results after 18 months
and to medium/long-term clinical outcomes [42]. Gener-
ally, a high nucleus volume, muscle cell mass index and
fibrous tissue mass index were related to advanced disease
characterized by impaired LV systolic and diastolic func-
tion, whereas the aortic valve gradient and wall stress did
not correlate with any of the histological variables. Eight-
een months after AVR, the LV mass index had decreased
significantly, but the relative mass reduction was unre-
lated to the postoperative peak Doppler gradient, the
diameter of the orifice of the prosthesis or the type of
valve (which were not evaluated using the indexed EOA
method). On the contrary, favorable remodeling was
inversely related to muscle cell diameter, nucleus volume,
percent fibrosis, the muscle cell mass index and the
fibrous tissue mass index observed at the time of AVR,
with the first two being the foremost determinants. More-
over, only 17% of the patients had a normal ventricular
mass, although significant hypertrophy regression did
take place. The extent of this regression after the removal
of the hemodynamic trigger therefore seems to be prede-
termined by the presence of presumably irreversible myo-Page 6 of 9
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particular survival was inversely related to myocardial
nucleus size (Fug.2). Prolonging the observation period
and charting the time course of the LV mass index con-
firmed the pattern of regression, which was highly signif-
icant during the first 1.5 years, after which there was no
further change up to 10 years. A lower LV mass index after
1.5 years was therefore a better predictor of long-term sur-
vival [17]. The potential for regression is the crucial point
when evaluating the correct timing of surgery in patients
with AS. The prognostic index developed by Lund et al.
can estimate this potential because of its significant corre-
lation with the LV mass index and long-term survival [17].
We have also searched for preoperative factors affecting
absolute LV mass regression and, after an intermediate
follow-up, we found that a higher preoperative LV mass
was an independent non-hemodynamic predictor of
greater regression (p < 0.0001), a finding that was also
confirmed in patients with PPM [18,19]. This may explain
why LV mass significantly regresses even in patients
receiving a small prosthesis, although it does not necessar-
ily mean that the regression is optimal or complete. Anal-
ysis of the data coming from a longer follow-up study
currently coming to an end at our institution should fur-
ther elucidate our preliminary findings concerning the
role of preoperative non-hemodynamic factors.
Hanayama et al. have recently found that, in addition to
male gender, the extent of preoperative hypertrophy was
the most important predictor of incomplete mass regres-
sion in a large study group and, like Gaudino et al. and
Lund et al. previously [15,17], suggested that earlier surgi-
cal intervention may reduce the extent of postoperative
residual hypertrophy and thus improve the outcome [17].
Conclusion
Over the last 50 years, aortic valve surgery has made enor-
mous strides towards the durable and physiological per-
formance of aortic valve prostheses, thus allowing the
restoration of normal LV structure and function. Interac-
tions between surgeons and physicians have not only led
to improvements in operative techniques and results, but
have also facilitated a better knowledge of LV pathophys-
iology. We now understand much more about the nature
of myocardial adaptation to pressure overload and myo-
cardial responses to AVR, but some limitations need to be
considered. The literature pertaining to the effects and
efficacy of surgery largely consists of heterogeneous stud-
ies of relatively small populations, and differences in
terms of patient selection, evaluated outcomes, operative
interventions, and the timing of postoperative follow-up
examinations limit their general applicability. Even the
apparent simplicity of evaluating LV hypertrophy by
means of echocardiography hides some intrinsic and
largely unrecognized critical steps that may sometimes
limit its clinical validity [48]. One positive note is that
some of the discrepancies (such as the prevalence of PPM)
are only apparent because an in-depth analysis may reveal
that certain types of prosthesis are no longer implanted:
for example, some studies included patients receiving the
bulky and no longer available Starr-Edwards ball-caged
valve [17], whereas many surgeons are now opting for
supra-annular prostheses that allow improved hemody-
namics even in small aortic annuli, and so better results
can be expected in the future [49]. Other surgical options
for minimizing PPM are also available, such as the
replacement of the entire aortic root or the aortic root
enlargement procedure described by Castro et al. [50],
which bears the same operative risk as standard AVR and
minimizes the incidence of PPM. In our institution, we
have concentrated on the question of subvalvular obstruc-
tion because it has been reported that fixed or dynamic
obstruction of the LV outflow tract after AVR is responsi-
ble for residual symptoms and incomplete hypertrophy
regression, and found that a strategy including myectomy-
myotomy before prosthetic valve implantation positively
influences LV mass regression and favorable LV remode-
ling (Additional File 1) [51].
Other often-overlooked factors affecting the postoperative
course are now emerging, such as ethnicity or arterial
hypertension [15,48,52,53]. In particular, high blood
pressure after AVR is gaining increasing attention as a
strong and independent determinant of slower and
incomplete mass regression. Research is also going for-
ward at cellular level, and we early demonstrated that
myocyte hyperplasia significantly contributes to LV hyper-
trophy: the increased cardiac mass associated with human
AS is due to a combination of myocyte hypertrophy and
hyperplasia, and intense new myocyte formation takes
place as a result of the differentiation of stem-like cells
committed to the myocyte lineage in response to an
increased workload [54]. These findings, together with the
identification of new environmental or genetic factors,
will lead to new interpretations of the maladaptative
mechanism of LV hypertrophy and the process of mass
regression at cellular level. Meanwhile randomized com-
parison of stentless versus stented valves failed to affirm
the superiority of stentless prosthesis. Actually, despite
significant differences in indexed EOA and peak flow
velocity in favor of the stentless valve, there were similar
reduction in LV mass at 6 months with both stented and
stentless valves, which persisted at 12 months [55].
Post-AVR residual hypertrophy is a complex and impor-
tant phenomenon and, although its incidence is decreas-
ing, it still represents a vexing problem that has an impact
on morbidity and, probably, mortality. There is no doubt
that meticulous blood pressure control and an optimized
drug regimen are fundamental, but the curative potentialPage 7 of 9
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different timing for AVR. Earlier surgery can also be con-
sidered for asymptomatic patients with moderate AS and
a low expected operative mortality who show a marked
hypertrophic myocardial response to the increased after-
load. No clinical trial has yet compared an early surgical
strategy based on the degree of myocardial hypertrophic
remodeling with the traditional timing mainly based on
symptoms and valve parameters, although the former
makes sense as it has been shown that preserved or
supranormal LV chamber performance can mask myocar-
dial tissue dysfunction and surgery could hypothetically
prevent it. However, surgery has already improved the
prognosis of patients with AS, and many intraoperative
options are now available to tailor the right operation for
each patient. In our experience, every effort should be
made if a small projected indexed EOA is expected to
choose a prosthesis with the best projected indexed EOA
and implant it adequately by adding other procedures,
such as myotomy-myectomy, that allow favorable remod-
eling and the long-term benefits of LV mass regression.
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